Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28448071 | 1.00 | SLC18A3 (0.57) | SLC18A3KMT2AALDH1A1KDM4ECA1 | |
| SCHEMBL10562193 | 1.00 | SLC18A3 (0.57) | SLC18A3KMT2AALDH1A1KDM4ECA1 | |
| SCHEMBL31122399 | 1.00 | SLC18A3 (0.57) | SLC18A3KMT2AALDH1A1KDM4ECA1 | |
| SCHEMBL30456355 | 1.00 | SLC18A3 (0.57) | SLC18A3KMT2AALDH1A1KDM4ECA1 | |
| SCHEMBL11245821 | 1.00 | SLC18A3 (0.57) | SLC18A3KMT2AALDH1A1KDM4ECA1 | |
| SCHEMBL30456604 | 1.00 | SLC18A3 (0.57) | SLC18A3KMT2AALDH1A1KDM4ECA1 | |
| SCHEMBL23595723 | 1.00 | SLC18A3 (0.57) | SLC18A3KMT2AALDH1A1KDM4ECA1 | |
| SCHEMBL13917788 | 1.00 | SLC18A3 (0.57) | SLC18A3KMT2AALDH1A1KDM4ECA1 | |
| SCHEMBL7343040 | 0.98 | SLC18A3 (0.59) | SLC18A3KMT2AALDH1A1KDM4ECA1 | |
| SCHEMBL304915 | 0.96 | SLC18A3 (0.56) | SLC18A3KMT2AALDH1A1KDM4ECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116390727-A | N-linked isoquinolinamides as LRRK2 inhibitors, pharmaceutical compositions and uses thereof | 默沙东有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| EP-1348765-B1 | Process for the preparation of optically active azabicyclo heptanone derivatives | COUNCIL SCIENT IND RES (IN) | 2006-05-24 | — | — | EP | claimed |
| CN-116390727-A | N-linked isoquinolinamides as LRRK2 inhibitors, pharmaceutical compositions and uses thereof | 默沙东有限责任公司 | 2023-07-04 | — | — | CN | disclosed |
| US-8273891-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-09-25 | — | — | US | disclosed |
| US-8106066-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100137288-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF | SCHUMACHER RICHARD | 2010-06-03 | — | — | US | disclosed |
| US-20070078147-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2007-04-05 | — | — | US | disclosed |
| EP-1348765-B1 | Process for the preparation of optically active azabicyclo heptanone derivatives | COUNCIL SCIENT IND RES (IN) | 2006-05-24 | — | — | EP | disclosed |
| EP-1348765-A1 | Process for the preparation of optically active azabicyclo heptanone derivatives | Council of Scientific and Industrial Research (IN) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137288-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA2 | SLC18A3 52/4885KMT2A 3238/4885ALDH1A1 1707/4885 |
| US-20070078147-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA2 | SLC18A3 52/4885KMT2A 3238/4885ALDH1A1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.